CN Patent

CN117222636A — 作为cdk4/6抑制剂的氘代化合物

Assigned to Gan and Lee Pharmaceuticals Co Ltd · Expires 2023-12-12 · 2y expired

What this patent protects

本发明涉及一种作为CDK4/6抑制剂的氘代化合物、其制备方法、含氘代化合物的药物组合物及其用途，相比于未氘代的对照化合物，具有更佳的代谢稳定性和更优异的药代动力学性质，有望降低临床的使用剂量。

USPTO Abstract

本发明涉及一种作为CDK4/6抑制剂的氘代化合物、其制备方法、含氘代化合物的药物组合物及其用途，相比于未氘代的对照化合物，具有更佳的代谢稳定性和更优异的药代动力学性质，有望降低临床的使用剂量。

Drugs covered by this patent

Patent Metadata

Patent number
CN117222636A
Jurisdiction
CN
Classification
—
Expires
2023-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Gan and Lee Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.